Bill116th CongressFiled Jan 8, 2019Health
H.R. 321
Neuromyelitis Optica Consortium Act
Bill journey · stage 2 of 5
Under committee review
FiledFiled
CommitteeComm.
PassedFloor
Both ChambersBoth
Became LawLaw
What it doesSummary introduced in house (Jan 8, 2019)
Neuromyelitis Optica Consortium Act
This bill requires the National Institutes of Health to establish, administer, and coordinate a national consortium on neuromyelitis optica (NMO), which is a neurological disease that can cause blindness and paralysis.
The consortium must
- award grants for research on the causes of, and the risk factors and biomarkers associated with, NMO;
- assemble a panel of experts to provide guidance and recommendations on research design and protocols; and
- designate a central laboratory to collect and analyze data from this research and to make the data and analysis available to researchers.
What just happenedJan 25, 2019
Referred to the Subcommittee on Health.
Who’s behind it
Rep. Lee, Barbara [D-CA-13](D-CA)Sponsor
1committees4actions9subjects
- Introduced in HouseJan 8, 2019
- Jan 25, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jan 8, 2019IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jan 8, 2019IntroReferralIntro-H
Introduced in House
- Jan 8, 2019IntroReferral1000
Introduced in House